Dr Reddy’s laboratories has launched lbandronate Sodium tablets (150 mg), a bioequivalent generic version of BONIVA tablets in the US market on June 29, 2012 following the approval by the United State Food & Drug Administration ( USFDA).
The company’s Ibandronates Sodium tablets in 150 mg are available in cartons of 3 blister packs containing 1 tablet each (once monthly dosing).
The BONIVA brand and generic had US sales of approximately $486 million for the most recent twelve months ending March 2012 according to IMS Health.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
